Although biomarker tests (or companion diagnostics) offer unprecedented capabilities, they ultimately qualify the minority of patients for precision medicine, while excluding the majority.

Precision medicine can no longer solely count on superiority in the field of biomarker testing. PGA can gap-fill biomarker testing to complete test menu, but it is not a substitute or replacement.

OncoDxRx unveils a new cell-free mRNA (cfmRNA)-based multi-biomarker drug efficacy prediction technology for patients with limited treatment options - with the unique simultaneous in vitro patient testing and in silico data computation, providing exceptional early drug response prediction, in particular for patients who are unresponsive to targeted therapy or immunotherapy.

Situational awareness in cancer treatment is critical to maintaining the therapeutic advantage. Yet the increasing heterogeneity of tumor is constantly challenging this advantage. The evolving of drug resistance, in particular targeted therapy, is significantly contributing to shifting cancer battlefield supremacy. High proliferation and the constant evolution of tumor clones in terms of dynamics, kinetics, immunosuppression and immune escaping increases the level of this threat day by day.

Providing coverage of the full spectrum of anticancer drugs in the field, PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) provides 360-degree mapping coverage for more than 700 drugs. The technology surveys a large volume in databases, with fast update rates, enabling accurate match and automatic ranking of effective drugs by IC50s or Z-scores, providing crucial information for clinical decision support.

Through a clear, simple data fusion interface, operators can easily recognize a potential match, gaining precious time to decide if and which drugs are likely to work in each individual patient. In complex clinical scenarios such as progressive, refractory disease or relapse, the ability to classify quickly to get a list of top-performance drugs (i.e., positive drug responses) provides a clinical advantage.

Thanks to its high-throughput and scalable configuration, PGA can be quickly set up and implemented. In 5 days, lab operators can deliver personalized reports. With its unmatched drug response predictive power, PGA provides clinicians with seamless situational awareness and high levels of actionable results.

As OncoDxRx accelerates its commercialization to meet the unprecedented clinical demand for its drug efficacy prediction technology, PGA stands at the forefront of a pivotal moment in precision medicine. This endeavor, driven by innovation, strategic foresight, and a commitment to improve clinical outcome, reflects the company’s resolve to navigate the complexities of contemporary diagnostics and therapeutics. The story of OncoDxRx and its PGA is not just about scaling up market shares; it's about shaping the future of global precision oncology landscapes.